AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16894411 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated single photon emission tomography (GSPET) at rest (examination I)
Number of subjects: 20
Study 16894411 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated single photon emission tomography (GSPET) at stress (examination I)
Number of subjects: 20
Study 16894411 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated single photon emission tomography (GSPET) at rest (examination II)
Number of subjects: 20
Study 16894411 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated single photon emission tomography (GSPET) at stress (examination II)
Number of subjects: 20
Study 16894411 — intervention group
Group type: COMPARATOR
Intervention: Comparison of EDV at rest and stress between examination I and II
Number of subjects: 20
Study 16894411 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ESV at rest and stress between examination I and II
Number of subjects: 20
Study 16894411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of myocardial perfusion defects at rest (examination I)
Number of subjects: 20
Study 16894411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of myocardial perfusion defects at stress (examination I)
Number of subjects: 20
Study 16894411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of myocardial perfusion defects at rest (examination II)
Number of subjects: 20
Study 16894411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of myocardial perfusion defects at stress (examination II)
Number of subjects: 20
Study 16894411 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between LVEF at rest and stress (examination I)
Number of subjects: 20
Study 16894411 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between LVEF at rest and stress (examination II)
Number of subjects: 20
Study 14692928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional 5-fluorouracil (5-FU) at weekly intervals for 12 weeks
Number of subjects: 28
Study 10480608 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeostasis model assessment (HOMA) using immunoreactive insulin
Number of subjects: 24
Study 10480608 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of glucose with model assessment (CIGMA) using immunoreactive insulin
Number of subjects: 24
Study 10480608 — intervention group
Group type: COMPARATOR
Intervention: First-phase intravenous glucose tolerance test (FSIVGTT)
Number of subjects: 24
Study 8942885 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical metronidazole applied to the lid margin in one eye
Number of subjects: 10
Study 8942885 — intervention group
Group type: COMPARATOR
Intervention: Lid hygiene alone in the fellow eye (Control)
Number of subjects: 10
Study 1962619 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms qid
Number of subjects: 91
Study 1962619 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms bid
Number of subjects: 91
Study 1962619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 6127966 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (0.77%)
Number of subjects: 15
Study 6127966 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic, oxybuprocain
Number of subjects: 15
Study 31450987 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior (DA) approach
Number of subjects: 100
Study 31450987 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral (PL) approach
Number of subjects: 100
Study 30167782 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day adjunctive raloxifene
Number of subjects: 14
Study 30167782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 28089366 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-times weekly in-center hemodialysis for an average of 14.6 hours
Number of subjects: 83
Study 28089366 — intervention group
Group type: COMPARATOR
Intervention: Three-times weekly in-center hemodialysis for an average of 10.9 hours
Number of subjects: 83
Study 25302927 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS-supplemented formula (0.4 g/100 mL)
Number of subjects: 362
Study 25302927 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS-supplemented formula
Number of subjects: 362
Study 25302927 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 362
Study 22689395 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical microemulsion containing metronidazole
Number of subjects: 0
Study 22689395 — intervention group
Group type: COMPARATOR
Intervention: Commercial gel product
Number of subjects: 0
Study 20503132 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Vibration (NV) for 20 minutes
Number of subjects: 0
Study 20503132 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Neck Vibration (NV) and Prism Adaptation (PA)
Number of subjects: 0
Study 20503132 — intervention group
Group type: COMPARATOR
Intervention: Neck Vibration (NV) only
Number of subjects: 0
Study 17661241 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 72
Study 17661241 — intervention group
Group type: COMPARATOR
Intervention: Cyanoacrylate
Number of subjects: 72
Study 16235062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone (400 microg)
Number of subjects: 29
Study 16235062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11919121 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet alone (30 kcal/kg per day)
Number of subjects: 36
Study 11919121 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with voglibose
Number of subjects: 36
Study 11919121 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with glyburide
Number of subjects: 36
Study 11919121 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 36
Study 10362186 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 20
Study 10362186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8720210 — intervention group
Group type: EXPERIMENTAL
Intervention: 90‐mu F capacitance
Number of subjects: 16
Study 8720210 — intervention group
Group type: COMPARATOR
Intervention: 120‐mu F capacitance
Number of subjects: 16
Study 1828205 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin plus lactobacilli
Number of subjects: 40
Study 1828205 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 40
Study 7050714 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX) 160 mg of TMP and 800 mg of SMX
Number of subjects: 110
Study 7050714 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP) alone 200 mg
Number of subjects: 110
Study 7050714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 30970056 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic therapy (including Berberis, Mercurius solubilis/Belladonna/Hepar sulphur, and Pyrogenium)
Number of subjects: 80
Study 30970056 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT) + Homeopathic therapy
Number of subjects: 80
Study 30970056 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 80
Study 29974280 — intervention group
Group type: EXPERIMENTAL
Intervention: He-Ne laser and topical treatment
Number of subjects: 15
Study 29974280 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment only
Number of subjects: 15
Study 27215244 — intervention group
Group type: EXPERIMENTAL
Intervention: Na/K citrate
Number of subjects: 210
Study 27215244 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate
Number of subjects: 210
Study 24699061 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod (7.5 mg BD) for 6 weeks
Number of subjects: 152
Study 22036832 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine cloths
Number of subjects: 0
Study 22036832 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing methods
Number of subjects: 0
Study 19560322 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER) 3, 6, 9, or 12 mg
Number of subjects: 1193
Study 19560322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1193
Study 17761460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with dutasteride and tamsulosin
Number of subjects: 4838
Study 17761460 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with dutasteride
Number of subjects: 4838
Study 17761460 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with tamsulosin
Number of subjects: 4838
Study 18193707 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 1001
Study 18193707 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 1001
Study 15161956 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF/reduced dose cyclosporin (0.5-1.0 g bd; C(0): 75-100 ng/ml)
Number of subjects: 42
Study 15161956 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus for cyclosporin (C(0): 5-10 ng/ml)
Number of subjects: 42
Study 15161956 — intervention group
Group type: COMPARATOR
Intervention: Continuation of standard therapy (C(0): 163 ng/ml (145-215 ng/ml))
Number of subjects: 42
Study 15161956 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF/reduced dose cyclosporin
Number of subjects: 42
Study 10627347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous regional analgesia preoperatively
Number of subjects: 36
Study 10627347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular analgesia
Number of subjects: 36
Study 10627347 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 36
Study 9010696 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 16
Study 9010696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1458772 — intervention group
Group type: COMPARATOR
Intervention: 0, 7.5, 15, and 30 micrograms/kg nicotine via nasal spray
Number of subjects: 36
Study 1458772 — intervention group
Group type: COMPARATOR
Intervention: 0, 15, and 30 micrograms/kg nicotine via nasal spray
Number of subjects: 36
Study 1458772 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms/kg nicotine via nasal spray
Number of subjects: 36
Study 1458772 — intervention group
Group type: COMPARATOR
Intervention: 15 and 30 micrograms/kg nicotine via nasal spray
Number of subjects: 36
Study 6233150 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) 20 mg twice a day for 2 weeks, then aminoglutethimide (AG) 250 mg four times a day
Number of subjects: 28
Study 6233150 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (HC) alone for 2 weeks
Number of subjects: 28
Study 6233150 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (HC) alone
Number of subjects: 28
Study 6233150 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) plus aminoglutethimide (AG) from day 1
Number of subjects: 28
Study 31437472 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 red/2 green TLL (2 negative/2 positive) food item with sugar labeled green
Number of subjects: 0
Study 31437472 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy content food items
Number of subjects: 0
Study 31437472 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy content food items
Number of subjects: 0
Study 30098353 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor cornea with preservation time (PT) of 0 to 7 days (n = 675)
Number of subjects: 1090
Study 30098353 — intervention group
Group type: COMPARATOR
Intervention: Donor cornea with preservation time (PT) of 8 to 14 days (n = 655)
Number of subjects: 1090
Study 30098353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue from donors with diabetes
Number of subjects: 1090
Study 30098353 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative complications
Number of subjects: 1090
Study 30098353 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative diagnosis of PACE
Number of subjects: 1090
Study 30098353 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor age
Number of subjects: 1090
Study 30098353 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative donor endothelial cell density
Number of subjects: 1090
Study 30098353 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft diameter
Number of subjects: 1090
Study 30098353 — intervention group
Group type: EXPERIMENTAL
Intervention: Injector use for graft insertion
Number of subjects: 1090
Study 26974440 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 0
Study 26974440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24202061 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercise (intervention group)
Number of subjects: 96
Study 24202061 — intervention group
Group type: COMPARATOR
Intervention: Sham exercise (control group)
Number of subjects: 96
Study 22935601 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% eye drops
Number of subjects: 90
Study 22935601 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 90
Study 19279298 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk reduction (RRR) information
Number of subjects: 113
Study 19279298 — intervention group
Group type: COMPARATOR
Intervention: Absolute risk reduction (ARR) information
Number of subjects: 113
Study 17448832 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser vaporization
Number of subjects: 82
Study 16329060 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior sub-tenon injection of triamcinolone acetonide (TA), 40 mg, repeated after 2 months
Number of subjects: 64
Study 16329060 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subconjunctival injection), repeated after 2 months
Number of subjects: 64
Study 12547661 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mcg oral contraceptive (OC)
Number of subjects: 43
Study 9653611 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg thrice daily
Number of subjects: 90
Study 9653611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 9653611 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 90
Study 8145275 — intervention group
Group type: EXPERIMENTAL
Intervention: Gail et al. model for predicting breast cancer risk
Number of subjects: 115172
Study 2687691 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 0.07 U/kg body weight, subcutaneously at bedtime
Number of subjects: 24
Study 2687691 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 4629980 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (D.S.C.G.)
Number of subjects: 117
Study 4629980 — intervention group
Group type: COMPARATOR
Intervention: Inactive preparation (placebo)
Number of subjects: 117
Study 30611286 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 115
Study 30611286 — intervention group
Group type: COMPARATOR
Intervention: Exergame training
Number of subjects: 115
Study 30611286 — intervention group
Group type: EXPERIMENTAL
Intervention: Active control (relaxation and flexibility exercises)
Number of subjects: 115
Study 28192113 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg levodropropizine
Number of subjects: 24
Study 28192113 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg dihydrocodeine
Number of subjects: 24
Study 28192113 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 24
Study 24711062 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST)
Number of subjects: 22
Study 24711062 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 22
Study 24326106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) guided by visual acuity stabilization criteria (group I, n = 106)
Number of subjects: 277
Study 24326106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) guided by disease activity criteria (group II, n = 116)
Number of subjects: 277
Study 24326106 — intervention group
Group type: COMPARATOR
Intervention: Verteporfin photodynamic therapy (vPDT) (group III, n = 55)
Number of subjects: 277
Study 24326106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) guided by disease activity criteria (group II)
Number of subjects: 277
Study 24326106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) guided by visual acuity stabilization criteria (group I)
Number of subjects: 277
Study 24326106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) (group I)
Number of subjects: 277
Study 24326106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) (group II)
Number of subjects: 277
Study 24326106 — intervention group
Group type: COMPARATOR
Intervention: Verteporfin photodynamic therapy (vPDT) (group III)
Number of subjects: 277
Study 24326106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment (both groups I and II)
Number of subjects: 277
Study 24326106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 277
Study 21993470 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen cross-linking (CXL)
Number of subjects: 69
Study 21993470 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 69
Study 21993470 — intervention group
Group type: COMPARATOR
Intervention: Fellow eye control
Number of subjects: 69
Study 19664345 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol (TB)
Number of subjects: 12
Study 19664345 — intervention group
Group type: COMPARATOR
Intervention: Oral mefenamic acid and intramuscular meperidine (M&M)
Number of subjects: 12
Study 17500380 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole gel 0.75%
Number of subjects: 36
Study 17500380 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid gel 15%
Number of subjects: 36
Study 17500380 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole gel 1%
Number of subjects: 36
Study 15841781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride gel (Group 2)
Number of subjects: 172
Study 15841781 — intervention group
Group type: COMPARATOR
Intervention: Simple lubrication (Group 1)
Number of subjects: 172
Study 12744480 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) at 0.05 mg/kg/day
Number of subjects: 11
Study 12744480 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 10482998 — intervention group
Group type: EXPERIMENTAL
Intervention: CD44s expression
Number of subjects: 276
Study 10482998 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of CD44s in the IPI parameter 'stage'
Number of subjects: 276
Study 10482998 — intervention group
Group type: EXPERIMENTAL
Intervention: CD44v6 expression
Number of subjects: 276
Study 7489600 — intervention group
Group type: EXPERIMENTAL
Intervention: 40cc IAB at assist ratio 1:1
Number of subjects: 20
Study 7489600 — intervention group
Group type: EXPERIMENTAL
Intervention: 32cc IAB at assist ratio 1:1
Number of subjects: 20
Study 7489600 — intervention group
Group type: COMPARATOR
Intervention: 40cc IAB at assist ratio 1:8
Number of subjects: 20
Study 7489600 — intervention group
Group type: COMPARATOR
Intervention: 32cc IAB at assist ratio 1:8
Number of subjects: 20
Study 1784030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin therapy (200 mg four times a day)
Number of subjects: 60
Study 1784030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7223696 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation from 6 months to 3 years
Number of subjects: 433
Study 7223696 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation during the 3rd trimester of pregnancy and the first 6 months of the child's life
Number of subjects: 433
Study 7223696 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation throughout the entire study period
Number of subjects: 433
Study 7223696 — intervention group
Group type: COMPARATOR
Intervention: Maternal education program without nutritional supplement
Number of subjects: 433
Study 7223696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nutritional supplementation and maternal education program
Number of subjects: 433
Study 7223696 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 433
Study 31551213 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000 IU weekly for 12 weeks
Number of subjects: 109
Study 31551213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 28396556 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for STIs during pregnancy
Number of subjects: 615
Study 28396556 — intervention group
Group type: COMPARATOR
Intervention: No treatment for STIs during pregnancy (control group)
Number of subjects: 615
Study 28396556 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital HSV-2 shedding
Number of subjects: 615
Study 28396556 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated curable STIs (T.vaginalis, C.trachomatis, N.gonorrhoea)
Number of subjects: 615
Study 27072817 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced web-based weight loss program with individualized feedback and reminders
Number of subjects: 301
Study 27072817 — intervention group
Group type: COMPARATOR
Intervention: Basic web-based weight loss program with limited feedback and reminders
Number of subjects: 301
Study 25186121 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 167
Study 25186121 — intervention group
Group type: COMPARATOR
Intervention: Family support (FS)
Number of subjects: 167
Study 25186121 — intervention group
Group type: EXPERIMENTAL
Intervention: MST
Number of subjects: 167
Study 22287681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried distillers grains (DDG) supplement
Number of subjects: 60
Study 22287681 — intervention group
Group type: COMPARATOR
Intervention: Steam-flaked corn based diet (SFC)
Number of subjects: 60
Study 22287681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried distillers grains (DDG) at 35% DM in steam-flaked corn-based finishing diets
Number of subjects: 60